Literature DB >> 31800942

[Detection of mutations causing Duchenne and Becker muscular dystrophies: multiplex polymerase chain reaction vs. Multiplex ligation dependent probe amplification].

Francia Dp Huamán-Dianderas1, María Luisa Guevara-Fujita1, Diana Rojas Málaga2, Alejandro Estrada-Cuzcano3, Ricardo Fujita1.   

Abstract

Duchenne and Becker muscular dystrophies are rare diseases that receive limited attention in our field. The objective of this study was to implement the Multiplex Ligation-dependent Probe Amplification technique (MLPA) and to demonstrate that it has advantages over the Multiplex Polymerase Chain Reaction (Multiplex PCR) technique. Samples from 40 individuals with a presumptive diagnosis of Duchenne and Becker muscular dystrophies were analyzed: first by Multiplex PCR and then by MLPA. Fifteen individuals with causal deletions were detected with Multiplex PCR, while the MLPA technique was able to diagnose 21 individuals, four duplications, and 17 deletions. In conclusion, the MLPA technique can detect mutations of the exon deletion and duplication type, yielding a larger number of molecular diagnoses due to alterations in the DMD gene.

Entities:  

Mesh:

Year:  2019        PMID: 31800942     DOI: 10.17843/rpmesp.2019.363.4085

Source DB:  PubMed          Journal:  Rev Peru Med Exp Salud Publica        ISSN: 1726-4634


  2 in total

1.  Genetic Profile of the Dystrophin Gene Reveals New Mutations in Colombian Patients Affected with Muscular Dystrophinopathy.

Authors:  Paula Triana-Fonseca; Juan Fernando Parada-Márquez; Claudia T Silva-Aldana; Daniela Zambrano-Arenas; Laura Lucia Arias-Gomez; Natalia Morales-Fonseca; Esteban Medina-Méndez; Carlos M Restrepo; Daniel Felipe Silgado-Guzmán; Dora Janeth Fonseca-Mendoza
Journal:  Appl Clin Genet       Date:  2021-10-01

2.  Theragnosis for Duchenne Muscular Dystrophy.

Authors:  Leonela Luce; Micaela Carcione; Chiara Mazzanti; Paula I Buonfiglio; Viviana Dalamón; Lilia Mesa; Alberto Dubrovsky; José Corderí; Florencia Giliberto
Journal:  Front Pharmacol       Date:  2021-06-03       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.